Compare · MRNA vs PLUR
MRNA vs PLUR
Side-by-side comparison of Moderna Inc. (MRNA) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $79.63B, about 6020.4x PLUR ($13.2M).
- MRNA has been more active in the news (16 items in the past 4 weeks vs 9 for PLUR).
- MRNA has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- Moderna Inc.
- Pluri Inc.
- Price
- -
- -
- Market cap
- $79.63B
- $13.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 16
- 9
- Recent ratings
- 25
- 0
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- President Stephen Hoge exercised 152,905 shares at a strike of $12.21, sold $16,900,019 worth of shares (78,375 units at $215.63) as part of a pre-agreed trading plan and gifted 400,000 shares, decreasing direct ownership by 20% to 1,311,095 units (SEC Form 4)
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest PLUR
- SEC Form SCHEDULE 13G filed by Pluri Inc.
- Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
- Amendment: SEC Form S-3/A filed by Pluri Inc.
- SEC Form 10-Q filed by Pluri Inc.
- Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion
- Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
- Director Manieu Alexandre Weinstein bought $1,250,001 worth of shares (833,334 units at $1.50) (SEC Form 4)
- Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
- Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company